Lurbinectedin - PharmaMar

Drug Profile

Lurbinectedin - PharmaMar

Alternative Names: PM-01183; PM-1183; Tryptamicidin; Zepsyre

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaMar
  • Developer Fundacion Instituto Valenciano de Oncologia; PharmaMar; Swiss Group for Clinical Cancer Research
  • Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Dioxolanes; Indoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; Cell cycle inhibitors; RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer; Small cell lung cancer
  • Phase II Breast cancer; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • No development reported Leukaemia

Most Recent Events

  • 21 Feb 2018 Interim efficacy and adverse events data from a phase III trial in small-cell-lung-cancer released by PharmaMar
  • 13 Nov 2017 Safety and efficacy data from the phase II BASKET trial in Solid tumours released by PharmaMar
  • 07 Nov 2017 Lurbinectedin licensed to Boryung Pharmaceutical for commercialisation in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top